tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ONC Stock Latest News

BeOne Medicines price target raised to $345 from $321 at JPMorgan
The FlyBeOne Medicines price target raised to $345 from $321 at JPMorgan
4d ago
ONC
BeOne Medicines price target raised to $349 from $311 at RBC Capital
PremiumThe Fly
BeOne Medicines price target raised to $349 from $311 at RBC Capital
5d ago
ONC
BeOne announces EC approval of Tevimbra in combination with chemotherapy
PremiumThe Fly
BeOne announces EC approval of Tevimbra in combination with chemotherapy
11d ago
ONC
Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
PremiumRatings
Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
17d ago
ONC
Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
PremiumCompany Announcements
Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
20d ago
ONC
Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers
PremiumCompany AnnouncementsJazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers
23d ago
ONC
JAZZ
BeiGene’s Promising Phase 2 Study on Waldenström Macroglobulinemia
Premium
Company Announcements
BeiGene’s Promising Phase 2 Study on Waldenström Macroglobulinemia
23d ago
ONC
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
Premium
The Fly
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
24d ago
ONC
BeOne Medicines price target raised to $321 from $317 at JPMorgan
PremiumThe Fly
BeOne Medicines price target raised to $321 from $317 at JPMorgan
24d ago
ONC
BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
PremiumRatings
BeiGene’s Robust Oncology Pipeline and Strategic Developments Justify Buy Rating with $300 Price Target
24d ago
ONC
Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
PremiumCompany Announcements
Beigene’s Promising Phase 1 Study on BGB-21447 for Metastatic Breast Cancer
24d ago
ONC
BeiGene’s Zanubrutinib Study: A Potential Game-Changer for B-Cell Lymphoma Treatment
PremiumCompany Announcements
BeiGene’s Zanubrutinib Study: A Potential Game-Changer for B-Cell Lymphoma Treatment
24d ago
ONC
Beigene’s Zanubrutinib Study: A Potential Game-Changer in Nephropathy Treatment?
PremiumCompany AnnouncementsBeigene’s Zanubrutinib Study: A Potential Game-Changer in Nephropathy Treatment?
24d ago
ONC
BeiGene’s Promising Phase 3 Study on Lung Cancer Treatment
Premium
Company Announcements
BeiGene’s Promising Phase 3 Study on Lung Cancer Treatment
24d ago
ONC
Beigene’s BGB-16673 Study: A Potential Game-Changer in B-Cell Malignancies
Premium
Company Announcements
Beigene’s BGB-16673 Study: A Potential Game-Changer in B-Cell Malignancies
24d ago
ONC
Beigene’s Promising Phase 3 Study on Lymphoma Treatment
PremiumCompany Announcements
Beigene’s Promising Phase 3 Study on Lymphoma Treatment
24d ago
ONC
BeiGene’s BGB-21447 Study: A Potential Game-Changer in B-Cell Malignancies
PremiumCompany Announcements
BeiGene’s BGB-21447 Study: A Potential Game-Changer in B-Cell Malignancies
24d ago
ONC
BeiGene’s CELESTIAL-RRCLL Study: A Potential Game-Changer for CLL/SLL Treatment
PremiumCompany Announcements
BeiGene’s CELESTIAL-RRCLL Study: A Potential Game-Changer for CLL/SLL Treatment
24d ago
ONC
BeiGene’s Promising Phase 1a/1b Study on BGB-A3055 in Solid Tumors: Market Implications
PremiumCompany Announcements
BeiGene’s Promising Phase 1a/1b Study on BGB-A3055 in Solid Tumors: Market Implications
25d ago
ONC
BeOne Medicines announces EMA issues positive opinion on Brukinsa tablets
PremiumThe FlyBeOne Medicines announces EMA issues positive opinion on Brukinsa tablets
26d ago
ONC
BeiGene’s Innovative Approach to HR+/HER2- Metastatic Breast Cancer: A Phase 1 Study Update
Premium
Company Announcements
BeiGene’s Innovative Approach to HR+/HER2- Metastatic Breast Cancer: A Phase 1 Study Update
26d ago
ONC
BeiGene’s Zanubrutinib Study Update: A Potential Game-Changer in B-Cell Lymphoma Treatment
Premium
Company Announcements
BeiGene’s Zanubrutinib Study Update: A Potential Game-Changer in B-Cell Lymphoma Treatment
26d ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >